Etrasimod
- Status:
- Red
- Decision Date:
- April 2024
Comments
RED
- NICE TA956. For treating moderately to severely active ulcerative colitis in people aged 16 and over. ICB commissioned.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again